We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


IDT Biologika Introduces Plans to Expand

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "IDT Biologika Introduces Plans to Expand "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
IDT Biologika GmbH, a global integrated contract manufacturer of vaccines and biopharmaceuticals, today introduced plans to expand its viral vaccine production capacity with the addition of a new high-speed filling line and additional lyophilisation capacity. The company also announced the addition of 80 employees to its workforce – an increase of approximately 11 % – to meet growth in demand for its biologics production.

Dr. Ralf Pfirmann, CEO of IDT Biologika, said, "We are proud to be one of the few industrial service manufacturers in the world with the capacity and expertise to handle large-scale campaign manufacture of various vaccines and biopharmaceuticals. In light of the resurgence of interest by large pharma in developing new vaccines and the planned expansion of our filling capacity, IDT remains well positioned to provide ongoing best-in-class service to these innovative companies; from the bench through clinical development and commercial production. In addition, as one of the premiere quality outsourcing partners in Europe for global biotech companies – particularly in the complex area of biologics – our recent workforce expansion will accommodate increased demand in this area, and ensure the highest levels of efficiency and quality for our customers.”

IDT Biologika expects to expand its extraordinarily flexible, multipurpose vaccine manufacturing facilities via the completion of its new high-speed viral vaccine line by mid-2013. This line will substantially expand fill-finish capacity and well position the company for anticipated growth in demand for this service. The company’s existing vaccine facility features two contained manufacturing lines with segregated operations for preparation of cells, virus propagation and virus purification. All IDT Biologika facilities have been inspected by international regulatory agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

"For the past two decades, we have and continue to invest in state-of-the-art facilities, design and human expertise,” continued Mr. Pfirmann. “In addition, beyond our equipment and technical know-how, we believe in taking a collaborative whole project approach that allows us to respond to customers’ needs in very short timeframes as opposed to working on a turnkey basis.